Basilea Pharmaceutica AG (BPMUF)
USD 47.5
(0.0%)
USD 47.5
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 183.29 Million CHF | -31.06% |
| 2022 | 265.85 Million CHF | -13.08% |
| 2021 | 305.87 Million CHF | -7.82% |
| 2020 | 331.84 Million CHF | 5.54% |
| 2019 | 314.42 Million CHF | -9.76% |
| 2018 | 348.43 Million CHF | -11.25% |
| 2017 | 392.6 Million CHF | 8.16% |
| 2016 | 363 Million CHF | -5.47% |
| 2015 | 384 Million CHF | 522.46% |
| 2014 | 61.69 Million CHF | 2.3% |
| 2013 | 60.3 Million CHF | 2.89% |
| 2012 | 58.61 Million CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 171.87 Million CHF | 0.0% |
| 2023 Q1 | 215.04 Million CHF | -19.11% |
| 2023 Q2 | 215.04 Million CHF | 0.0% |
| 2023 Q3 | 183.29 Million CHF | -14.77% |
| 2023 Q4 | 183.29 Million CHF | -0.0% |
| 2023 FY | 183.29 Million CHF | -31.06% |
| 2022 Q1 | 303.23 Million CHF | -0.86% |
| 2022 Q3 | 241.56 Million CHF | -20.34% |
| 2022 Q4 | 265.85 Million CHF | 10.06% |
| 2022 FY | 265.85 Million CHF | -13.08% |
| 2022 Q2 | 303.23 Million CHF | 0.0% |
| 2021 Q3 | 305.87 Million CHF | -0.02% |
| 2021 Q1 | 305.92 Million CHF | -7.81% |
| 2021 FY | 305.87 Million CHF | -7.82% |
| 2021 Q2 | 305.92 Million CHF | 0.0% |
| 2021 Q4 | 305.87 Million CHF | 0.0% |
| 2020 Q3 | 331.84 Million CHF | 19.96% |
| 2020 Q4 | 331.84 Million CHF | 0.0% |
| 2020 Q1 | 276.63 Million CHF | -12.02% |
| 2020 FY | 331.84 Million CHF | 5.54% |
| 2020 Q2 | 276.63 Million CHF | 0.0% |
| 2019 Q2 | 315.63 Million CHF | 0.0% |
| 2019 Q4 | 314.42 Million CHF | 0.0% |
| 2019 Q1 | 315.63 Million CHF | -9.42% |
| 2019 Q3 | 314.42 Million CHF | -0.38% |
| 2019 FY | 314.42 Million CHF | -9.76% |
| 2018 FY | 348.43 Million CHF | -11.25% |
| 2018 Q4 | 348.43 Million CHF | 0.0% |
| 2018 Q3 | 348.43 Million CHF | -4.1% |
| 2018 Q2 | 363.33 Million CHF | 0.0% |
| 2018 Q1 | 363.33 Million CHF | -7.46% |
| 2017 Q2 | 344.54 Million CHF | 0.0% |
| 2017 FY | 392.6 Million CHF | 8.16% |
| 2017 Q4 | 392.6 Million CHF | 0.0% |
| 2017 Q3 | 392.6 Million CHF | 13.95% |
| 2017 Q1 | 344.54 Million CHF | -5.02% |
| 2016 Q3 | 362.75 Million CHF | 2.29% |
| 2016 FY | 363 Million CHF | -5.47% |
| 2016 Q2 | 354.62 Million CHF | 0.0% |
| 2016 Q1 | 354.62 Million CHF | -7.62% |
| 2016 Q4 | 362.75 Million CHF | 0.0% |
| 2015 FY | 384 Million CHF | 522.46% |
| 2015 Q4 | 383.87 Million CHF | 0.0% |
| 2015 Q3 | 383.87 Million CHF | 494.76% |
| 2015 Q1 | 64.54 Million CHF | 4.62% |
| 2015 Q2 | 64.54 Million CHF | 0.0% |
| 2014 Q1 | 53.15 Million CHF | -11.86% |
| 2014 Q3 | 61.69 Million CHF | 16.06% |
| 2014 Q2 | 53.15 Million CHF | 0.0% |
| 2014 FY | 61.69 Million CHF | 2.3% |
| 2014 Q4 | 61.69 Million CHF | 0.0% |
| 2013 FY | 60.3 Million CHF | 2.89% |
| 2013 Q1 | 55.31 Million CHF | -5.62% |
| 2013 Q2 | 55.31 Million CHF | 0.0% |
| 2013 Q3 | 60.3 Million CHF | 9.01% |
| 2013 Q4 | 60.3 Million CHF | 0.0% |
| 2012 Q4 | 58.61 Million CHF | 0.0% |
| 2012 Q3 | 58.61 Million CHF | 0.0% |
| 2012 FY | 58.61 Million CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -21753.345% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -7184.066% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -3461.791% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -152.916% |
| GB Sciences, Inc. | 5.41 Million USD | -3283.278% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -4900.895% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -11601.589% |
| Skye Bioscience, Inc. | 14.07 Million USD | -1202.502% |
| Zenith Capital Corp. | 27.56 Thousand USD | -664744.572% |
| Agentix Corp. | 2.51 Million USD | -7200.816% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1836.325% |
| Biomind Labs Inc. | 1.49 Million USD | -12130.717% |
| ContraFect Corporation | 32.53 Million USD | -463.435% |
| CSL Limited | 18.62 Billion USD | 99.016% |
| CytoDyn Inc. | 127.89 Million USD | -43.315% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -12683.038% |
| Neon Bloom, Inc. | 1.22 Million USD | -14847.729% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -144.649% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -409983.676% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -4659.045% |
| Regen BioPharma, Inc. | 5.45 Million USD | -3258.444% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -210.589% |
| SQZ Biotechnologies Company | 50.03 Million USD | -266.296% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -9018.365% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -243.853% |
| Intellipharmaceutics International Inc. | 12 Million USD | -1426.31% |
| Mesoblast Limited | 188.44 Million USD | 2.735% |
| Marizyme, Inc. | 26.67 Million USD | -587.108% |
| Genus plc | 485 Million USD | 62.208% |
| Pharming Group N.V. | 244.07 Million USD | 24.903% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -4723.447% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -4688.606% |
| IMV Inc. | 37.93 Million USD | -383.199% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1456.189% |
| MultiCell Technologies, Inc. | 1617.67 USD | -11330455.676% |
| ONE Bio Corp. | 27.49 Million USD | -566.614% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -136.758% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -121.006% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1927.063% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -895.962% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -128891.872% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -91036.956% |
| Alpha Cognition Inc. | 7.16 Million USD | -2458.224% |
| Enzolytics Inc. | 365.26 Million USD | 49.82% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 58.806% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -10593.757% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -640.689% |
| Genscript Biotech Corporation | 1.32 Billion USD | 86.176% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1812.863% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -43378.395% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -4808.302% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -26821.54% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -6659.412% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -3037.137% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -9151.01% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 1.07 Million USD | -16883.356% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -273758.865% |
| EV Biologics, Inc. | 2.11 Million USD | -8565.958% |
| Q BioMed Inc. | 8.13 Million USD | -2153.687% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -264.657% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -54.386% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -1052.435% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -3089.988% |
| HST Global, Inc. | 593.59 Thousand USD | -30778.228% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -668040.561% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -14456.228% |
| Halberd Corporation | 728.71 Thousand USD | -25052.494% |
| Resverlogix Corp. | 67.39 Million USD | -171.961% |
| Cell Source, Inc. | 15.8 Million USD | -1059.577% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1439.859% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 3.99 Million USD | -4489.452% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -76701.981% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | -2231.729% |
| Kadimastem Ltd | 3.5 Million USD | -5129.614% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -8834.204% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -39342.951% |
| LadRx Corporation | 2.2 Million USD | -8229.41% |
| Regen BioPharma, Inc. | 5.45 Million USD | -3258.444% |
| Affymax, Inc. | 8.87 Million USD | -1966.182% |
| Itoco Inc. | 1.65 Million USD | -10987.372% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -2930.104% |
| Mobile Lads Corp. | 1.31 Million USD | -13854.429% |
| International Stem Cell Corporation | 5.27 Million USD | -3373.394% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.24 Million USD | -5540.591% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -438405.706% |
| Qrons Inc. | 1.48 Million USD | -12212.044% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -1559.45% |
| SYBLEU INC | 681.41 Thousand USD | -26798.665% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -22562.26% |
| Rebus Holdings, Inc. | 5.24 Million USD | -3396.585% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -2903.832% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -29188.649% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -3869.808% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -347.095% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -723.225% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -8949.678% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -3245.947% |
| Neutra Corp. | 973.52 Thousand USD | -18727.482% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -531.711% |
| PureTech Health plc | 125.58 Million USD | -45.952% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -4778.491% |
| IXICO plc | 1.9 Million USD | -9545.412% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -792.839% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -77.394% |
| CSL Limited | 18.62 Billion USD | 99.016% |
| Cellectis S.A. | 249.36 Million USD | 26.498% |